Clinical Trial Update: Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma [Phase 1]

View source ↗

Summary

Phase 1 trial investigating imatinib mesylate in malignant glioma included tumor tissue analyses to assess biological effects of the drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Brain and Central Nervous System Tumors | Phase 1 | Status: COMPLETED